(S (S (NP (NNS Drugs)) (VP (VBP are) (ADVP (RB frequently)) (VP (VBN prescribed) (PP (TO to) (NP (NNS patients))) (PP (IN with) (NP (NP (DT the) (NN aim)) (PP (IN of) (S (VP (VBG improving) (NP (NP (DT each) (NN patient) (POS 's)) (JJ medical) (NN state)))))))))) (, ,) (CC but) (S (NP (NP (DT an) (JJ unfortunate) (NN consequence)) (PP (IN of) (NP (JJS most) (NN prescription) (NNS drugs)))) (VP (VBZ is) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ undesirable) (NN side) (NNS effects)))))) (. .))
(S (S (NP (NP (NN Side) (NNS effects)) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (IN in) (NP (QP (JJR more) (IN than) (CD one) (IN in) (DT a) (NN thousand)) (NNS patients))))))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (VP (VBN signalled) (ADVP (RB efficiently)) (PP (IN by) (NP (JJ current) (NN drug) (NN surveillance) (NNS methods)))))))))) (, ,) (S (ADVP (RB however)) (, ,) (NP (DT these) (JJ same) (NNS methods)) (VP (MD may) (VP (VB take) (NP (NNS decades)) (PP (IN before) (S (VP (VBG generating) (NP (NP (NNS signals)) (PP (IN for) (NP (JJ rarer) (NN side) (NNS effects))))))) (, ,) (S (VP (VBG risking) (NP (NP (JJ medical) (NN morbidity) (CC or) (NN mortality)) (PP (IN in) (NP (NP (NNS patients)) (VP (IN prescribed) (NP (DT the) (NN drug)))))) (SBAR (IN while) (S (NP (DT the) (JJ rare) (NN side) (NN effect)) (VP (VBZ is) (ADJP (JJ undiscovered)))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ novel) (JJ computational) (NN meta-analysis) (NN framework)) (PP (IN for) (S (VP (VBG signalling) (NP (JJ rare) (NN side) (NNS effects))))) (SBAR (WHNP (WDT that)) (S (VP (VBZ integrates) (NP (NP (VBG existing) (NNS methods)) (, ,) (NP (NP (NN knowledge)) (PP (IN from) (NP (DT the) (NN web)))) (, ,) (NP (JJ metric) (NN learning)) (CC and) (NP (JJ semi-supervised) (NN clustering)))))))) (. .))
(S (NP (DT The) (JJ novel) (NN framework)) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (VP (VB signal) (NP (NP (JJ many) (VBN known) (ADJP (JJ rare) (CC and) (JJ serious)) (NN side) (NNS effects)) (PP (IN for) (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN investigated)))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ tendon) (NN rupture)) (SBAR (WHADVP (WRB when)) (S (VP (VBN prescribed) (NP (NNP Ciprofloxacin) (CC or) (NNP Levofloxacin)))))) (, ,) (NP (NP (JJ renal) (NN failure)) (PP (IN with) (NP (NNP Naproxen)))) (CC and) (NP (NP (NN depression)) (VP (VBN associated) (PP (IN with) (NP (NNP Rimonabant))))))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (PP (IN for) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NP (DT the) (NN drug)) (VP (VBD investigated)))))) (NP (PRP it)) (VP (VP (VBD generated) (NP (NP (NNS signals)) (PP (IN for) (NP (JJ rare) (NN side) (NNS effects)))) (PP (IN at) (NP (NP (DT a) (ADJP (RBR more) (JJ stringent)) (VBG signalling) (NN threshold)) (PP (IN than) (NP (VBG existing) (NNS methods)))))) (CC and) (VP (VBZ shows) (NP (DT the) (JJ potential) (S (VP (TO to) (VP (VB become) (NP (NP (DT a) (JJ fundamental) (NN part)) (PP (IN of) (NP (NN post) (NN marketing) (NN surveillance))) (S (VP (TO to) (VP (VB detect) (NP (JJ rare) (NN side) (NNS effects)))))))))))) (. .))
